InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

SUTRO BIOPHARMA, INC.

STRO Clue Score56
United States Fiscal year ends December CIK 0001382101
$14.27 -6.85% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $14.27 −23.32% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 27 Sep 2018. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue59.7Operating income1.4Net income1.7Fiscal year 2017Revenue51.7 −13.4%Operating income−19.3Net income−19.7 −1,256.8%Fiscal year 2018Revenue38.4 −25.7%Operating income−37.2Net income−35.3Fiscal year 2019Revenue42.7 +11.2%Operating income−55.5Net income−119.2Fiscal year 2020Revenue42.7 −0.0%Operating income−71.1Net income−32.1EPS, diluted−0.99Fiscal year 2021Revenue61.9 +44.8%Operating income−98.5Net income−105.5EPS, diluted−2.29Fiscal year 2022Revenue67.8 +9.5%Operating income−128.9Net income−119.2EPS, diluted−2.35Fiscal year 2023Revenue153.7 +126.8%Operating income−89.3Net income−106.8EPS, diluted−1.78Fiscal year 2024Revenue62.0 −59.6%Operating income−238.5Net income−227.5EPS, diluted−29.40Fiscal year 2025Revenue102.5 +65.2%Operating income−158.4Net income−191.1EPS, diluted−22.49
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 59.7 51.7 38.4 42.7 42.7 61.9 67.8 153.7 62.0 102.5
Growth −13.4% −25.7% +11.2% −0.0% +44.8% +9.5% +126.8% −59.6% +65.2%
Operating income 1.4 −19.3 −37.2 −55.5 −71.1 −98.5 −128.9 −89.3 −238.5 −158.4
Net income 1.7 −19.7 −35.3 −119.2 −32.1 −105.5 −119.2 −106.8 −227.5 −191.1
Growth −1,256.8%
EPS, diluted n/a n/a n/a n/a −0.99 −2.29 −2.35 −1.78 −29.40 −22.49

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Operating margin2.3%Net margin2.8%Free cash flow margin−29.4%Fiscal year 2017Operating margin−37.2%Net margin−38.1%Free cash flow margin−78.1%Fiscal year 2018Operating margin−96.9%Net margin−91.9%Free cash flow margin29.0%Fiscal year 2019Operating margin−129.8%Net margin−278.9%Fiscal year 2020Operating margin−166.3%Net margin−75.2%Fiscal year 2021Operating margin−159.2%Net margin−170.6%Fiscal year 2022Operating margin−190.3%Net margin−175.9%Fiscal year 2023Operating margin−58.1%Net margin−69.5%Fiscal year 2024Operating margin−384.3%Net margin−366.6%Fiscal year 2025Operating margin−154.5%Net margin−186.5%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin 2.3% −37.2% −96.9% −129.8% −166.3% −159.2% −190.3% −58.1% −384.3% −154.5%
Net margin 2.8% −38.1% −91.9% −278.9% −75.2% −170.6% −175.9% −69.5% −366.6% −186.5%
Free cash flow margin −29.4% −78.1% 29.0% n/a n/a n/a n/a n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−13.2Capital expenditure−4.4Free cash flow−17.5Fiscal year 2017Operating cash flow−37.1Capital expenditure−3.3Free cash flow−40.4Fiscal year 2018Operating cash flow12.7Capital expenditure−1.6Free cash flow11.1Fiscal year 2019Operating cash flow−65.0Fiscal year 2020Operating cash flow−67.8Fiscal year 2021Operating cash flow−81.7Buybacks−0.0Fiscal year 2022Operating cash flow3.5Fiscal year 2023Operating cash flow−111.6Fiscal year 2024Operating cash flow−191.5Fiscal year 2025Operating cash flow−177.2
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −13.2 −37.1 12.7 −65.0 −67.8 −81.7 3.5 −111.6 −191.5 −177.2
Capital expenditure −4.4 −3.3 −1.6 n/a n/a n/a n/a n/a n/a n/a
Free cash flow −17.5 −40.4 11.1 n/a n/a n/a n/a n/a n/a n/a
Growth
Buybacks n/a n/a n/a n/a n/a −0.0 n/a n/a n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2016Cash11.6Shareholders’ equity−90.9Fiscal year 2017Cash22.0Shareholders’ equity−109.0Fiscal year 2018Cash125.3Total debt10.0Net cash (debt)115.3Shareholders’ equity131.5Debt to equity0.08Fiscal year 2019Cash5.0Total debt8.9Net cash (debt)−3.9Shareholders’ equity97.8Debt to equity0.09Fiscal year 2020Cash206.2Total debt24.5Net cash (debt)181.6Shareholders’ equity332.0Debt to equity0.07Fiscal year 2021Cash30.4Total debt25.1Net cash (debt)5.3Shareholders’ equity252.6Debt to equity0.10Fiscal year 2022Cash47.3Total debt16.3Net cash (debt)31.0Shareholders’ equity217.0Debt to equity0.07Fiscal year 2023Cash69.3Total debt4.1Net cash (debt)65.2Shareholders’ equity149.6Debt to equity0.03Fiscal year 2024Cash190.3Shareholders’ equity44.6Fiscal year 2025Cash58.1Shareholders’ equity−132.5
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 11.6 22.0 125.3 5.0 206.2 30.4 47.3 69.3 190.3 58.1
Total debt n/a n/a 10.0 8.9 24.5 25.1 16.3 4.1 n/a n/a
Net cash (debt) n/a n/a 115.3 −3.9 181.6 5.3 31.0 65.2 n/a n/a
Shareholders’ equity −90.9 −109.0 131.5 97.8 332.0 252.6 217.0 149.6 44.6 −132.5
Debt to equity n/a n/a 0.08 0.09 0.07 0.10 0.07 0.03 n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
59.7 51.7 38.4 42.7 42.7 61.9 67.8 153.7 62.0 102.5
Growth −13.4% −25.7% +11.2% −0.0% +44.8% +9.5% +126.8% −59.6% +65.2%
43.6 54.6 54.3 65.6 77.0 104.4 137.2 180.4 252.0 166.4
14.8 16.4 21.4 32.6 36.8 56.0 59.5 62.6 48.5 41.0
1.4 −19.3 −37.2 −55.5 −71.1 −98.5 −128.9 −89.3 −238.5 −158.4
Growth −1,512.9%
n/a n/a n/a n/a −32.0 −105.5 −116.7 −88.6 −225.1 −191.2
n/a 0.0 0.0 0.0 0.1 0.0 2.5 18.2 2.4 −0.1
1.7 −19.7 −35.3 −119.2 −32.1 −105.5 −119.2 −106.8 −227.5 −191.1
Growth −1,256.8%
Per share
n/a n/a n/a n/a −0.99 −2.29 −2.35 −1.78 −29.40 −22.49
n/a n/a n/a n/a −0.99 −2.29 −2.35 −1.78 −29.40 −22.49
Growth
n/a n/a n/a n/a 32.6 46.1 50.7 60.2 7.7 8.5
n/a n/a n/a n/a 32.6 46.1 50.7 60.2 7.7 8.5
Growth +41.6% +10.0% +18.6% −87.1% +9.8%

† The diluted share count jumps at 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 19.1% a year over five years.
  • Operating margin is up 11.8 points on five years ago, at -154.5%.
  • A net loss in 9 of 10 years on file.